A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation - Trial 2019-002189-11
Access comprehensive clinical trial information for 2019-002189-11 through Pure Global AI's free database. This phase not specified trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently status unknown. The study focuses on Cystic Fibrosis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2019-002189-11
Trial Details
EU Clinical Trials Register • 2019-002189-11
A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Study Focus
Sponsor & Location
Vertex Pharmaceuticals Incorporated
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
Change in CT imaging score from baseline at Week 72
ICD-10 Classifications
Cystic fibrosis
Cystic fibrosis, unspecified
Cystic fibrosis with other manifestations
Cystic fibrosis with pulmonary manifestations
Cystic fibrosis with intestinal manifestations
Data Source
EU Clinical Trials Register
2019-002189-11
Non-Device Trial